

Magnetic resonance spectroscopy of anoxic brain injury after cardiac arrest

Author(s):

Jong Woo Lee, MD, PhD; Lasya Sreepada, BS; Matthew Bevers, MD, PhD; Karen Li, BBA; Benjamin Scirica, MD; Danuzia Santana da Silva, RN, BSN, MPH; Galen V. Henderson, MD; Camden Bay, PhD; Alexander P Lin, PhD

Corresponding Author:

Alexander P Lin
aplin@bwh.harvard.edu

Affiliation Information for All Authors: Jong Woo Lee, Department of Neurology, Brigham and Women's Hospital, Boston, MA

Lasya Sreepada, Department of Radiology, Brigham and Women's Hospital, Boston, MA

Matthew Bevers, Department of Neurology, Brigham and Women's Hospital, Boston, MA

Karen Li, Department of Neurology, Brigham and Women's Hospital, Boston, MA

Benjamin Scirica, Department of Medicine, Division of Cardiology, Brigham and Women's Hospital, Boston, MA

Danuzia Silva, Department of Medicine, Division of Cardiology, Brigham and Women's Hospital, Boston, MA

Galen V. Henderson, Department of Neurology, Brigham and Women's Hospital, Boston, MA

Camden Bay, Department of Radiology, Brigham and Women's Hospital, Boston, MA

Alexander Lin, Department of Radiology, Brigham and Women's Hospital, Boston, MA

Contributions:

Jong Woo Lee: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Lasya Sreepada: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Matthew Bevers: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Karen Li: Analysis or interpretation of data

Benjamin Scirica: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design

Danuzia Santana da Silva: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Galen V. Henderson: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design

Camden Bay: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Alexander P Lin: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Number of characters in title: 75

Abstract Word count: 250

Word count of main text: 4498

References: 42

Figures: 4

Tables: 3

Supplemental: Response to Reviewers Updated STROBE Checklist

Statistical Analysis performed by: Camden Bay, PhD

Search Terms: [290] Cardiac, [284] EEG; see Epilepsy/Seizures (S), [62] EEG, [120] MRI, [125] MRS

Study Funding: The authors report no targeted funding

Disclosures:

Jong Woo Lee has performed contract work for Teladoc and Bioserenity, he was the site PI for Engage Therapeutics, he has received research funding from the NINDS, he is the co-founder of Soterya, Inc;

Lasya Sreepada reports no disclosures relevant to the manuscript;

Matthew Bevers is supported by grants from the American Academy of Neurology and National Institute of Neurologic Disorders and Stroke, he reports research funding and personal fees from Biogen, outside the scope of the current work;

Karen Li reports no disclosures relevant to the manuscript;

Benjamin Scirica reports Institutional research grant to Brigham and Women's Hospital from AstraZeneca, Eisai, Novartis, and Merck, consulting fees from AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, Covance, Eisai, Elsevier Practice Update Cardiology, GlaxoSmithKline, Lexicon, Medtronic, Merck, NovoNordisk, Sanofi, and equity in Health [at] Scale, is a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women's Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, Zora Biosciences;

Danuzia Silva reports no disclosures relevant to the manuscript;

Galen V. Henderson reports no disclosures relevant to the manuscript;

Camden Bay reports no disclosures relevant to the manuscript; Alexander Lin is a consultant for Agios Pharmaceuticals, Biomarin Pharmaceuticals, Moncton MRI and is cofounder of BrainSpec. He receives research funding from NINDS, NIA, Department of Defense, and the Alzheimers Association.

1 **Abstract**

2 **Objective:**

3 We describe magnetic resonance spectroscopy (MRS) changes in comatose patients
4 undergoing targeted temperature management (TTM) after cardiac arrest, and their
5 relationships to relevant clinical, MRI, and EEG variables.

6 **Methods**

7 A prospective cohort of 50 patients was studied. The primary outcome was coma recovery to
8 follow commands. Comparison of MRS measures in the posterior cingulate gyrus, parietal white
9 matter, basal ganglia, and brainstem were also made to 25 normative control subjects.

10 **Results:**

11 Fourteen of 50 achieved coma recovery. Compared to patients who recovered, there was a
12 significant decrease in total N-acetyl-aspartate (NAA/Cr) and glutamate; and an increase in
13 lactate (Lac/Cr) and glutamine in patients who did not recover, with changes most prominent in
14 the posterior cingulate gyrus. Patients who recovered had a decrease in NAA/Cr as compared
15 to control subjects. Coma recovery was seen in patients with a moderate decrease in NAA/Cr,
16 but the appearance of lactate resulted in a poor outcome. NAA/Cr had a linear relationship with
17 MRI cortical apparent diffusion coefficient (ADC); lactate level exponentially increased with
18 decreasing ADC. EEG suppression/burst suppression was universally associated with lactate
19 elevation.

20 **Conclusions**

21 NAA and lactate changes are associated with clinical/MRI/EEG changes consistent with anoxic
22 brain injury and are most prominent in the posterior cingulate gyrus. NAA/Cr decrease observed
23 in patients with good outcomes suggests mild anoxic injury in patients asymptomatic at hospital
24 discharge. The appearance of cortical lactate represents a deterioration of aerobic energy
25 metabolism and is associated with EEG background suppression, synaptic transmission failure,
26 and severe, potentially irreversible anoxic injury.

27 **Introduction:**

28 Anoxic brain injury represents the leading cause of mortality and long-term disability after
29 cardiac arrest. More than 350,000 adults suffer out-of-hospital cardiac arrest annually in the
30 United States, after which up to 80% remain comatose immediately thereafter.¹ As clinical
31 examination may not be sufficiently informative after targeted temperature management (TTM)²,
32 ancillary tests have been utilized to assess prognosis, including EEG, somatosensory evoked
33 potential (SSEP), MRI, and neuron specific enolase (NSE).

34 MR spectroscopy (MRS) has been utilized along with these other measures in assessing
35 prognosis.³ Few studies have examined the range of changes observed in brain-specific
36 metabolic markers through MRS in adult patients undergoing TTM. In neonatal patients
37 undergoing TTM for hypoxic-ischemic injury due to birth asphyxia, changes in NAA and choline
38 (Cho) levels, as measured by MRS, were associated with clinical outcome after TTM, though
39 there is disagreement regarding the utility of the measurement of lactate (Lac) or the optimal
40 brain region to be examined.^{4,5} Furthermore, previous studies have focused on brain regions
41 such as the pons, basal ganglia, thalamus, and corpus callosum which for technical reasons
42 may not provide the most sensitive measure for MRS changes after cardiac arrest. The wide
43 array of metabolites assessed by MRS allows for simultaneous assessment of both neuronal
44 integrity and aerobic metabolism, both of which are primary pathologies in anoxic brain injury.

45 We examine changes of several metabolites, as measured by MRS, in patients
46 comatose after cardiac arrest, comparing 1) patients with good vs poor neurological outcome; 2)
47 patients with anoxic brain injury to normative control subjects in the posterior cingulate gyrus
48 (PCG), parietal white matter (PWM), basal ganglia (BG), and brainstem (BS). These results are
49 placed in the context of their EEG and conventional MRI changes to identify and quantify
50 markers of anoxic brain injury after TTM and to determine brain regions that are preferentially
51 affected in anoxic brain injury.

52

53 **Methods:**

54 **Patient cohort and clinical outcome:**

55 This is a single-center prospective study of patients who underwent TTM for coma after
56 cardiac arrest and return of spontaneous circulation (ROSC) at the Brigham and Women's
57 Hospital between October 2016 and November 2020. Normative control subjects consisted of
58 25 athletic male volunteers without a history of head trauma or neurological disease, between
59 ages 45 and 70 (mean 57.9 ± 7.0).

60 The following data points were collected: age, sex, and pulseless rhythm at the time of
61 arrest (ventricular fibrillation/shockable vs pulseless electrical activity/asystole). Clinical exam
62 findings included pupillary light response, corneal reflex, and motor response. Motor findings
63 were dichotomized as flexor response or better (including flexion, withdrawal localization, or
64 normal function) versus extensor response, triple-flexion, or no response. Motor function was
65 scored based on the best response in either the upper or lower extremities.

66 The main clinical outcome was defined as **coma recovery** in those patients who
67 regained the ability to open eyes and follow commands before hospital discharge; any response
68 less than this was considered a poor outcome. As some patients were able to follow commands
69 but were still cognitively impaired, we identified patients with a cognitive return to baseline.
70 Cerebral performance category (CPC) at discharge were binarized to good (CPC 1-2) or poor
71 (CPC 3-5) outcome.⁶

72 **Cardiac arrest protocol:**

73 TTM was performed according to the previously published local protocol.⁷ Eligible resuscitated
74 cardiac arrest patients received TTM at 33°C or 36°C for 24 hours, using ice packs and a
75 surface cooling device (Arctic Sun System, Medivance, Louisville, CO). Patients were intubated
76 and sedated for 24 h with Propofol (0-83 mcg/kg/min) or midazolam (0-3 mg/h), and fentanyl (25
77 mcg/h). Cisatracurium (0.15 mg/kg IV q10min PRN, escalated to infusion at 0.5 mcg/kg/min for
78 persistent shivering) was administered for shivering. After 24 hours, patients were rewarmed by

79 0.25°C/hour. When clinically feasible, sedation was lightened after return to normothermia for
80 clinical assessments. Withdrawal of life-sustaining treatment (WLST) was performed on a case-
81 by-case basis through informed decision-making by the patient's family or guardian in close
82 collaboration with the medical team and the patient's family members.

83 **EEG**

84 Continuous video EEG (cEEG) monitoring (Natus XLTEK system, Pleasanton, CA) was placed
85 according to the international 10-20 system as soon as possible after starting TTM. Patients
86 were recorded for a minimum of 24h after normothermia was achieved. EEG data were
87 interpreted using the American Clinical Neurophysiology Society (ACNS) critical care EEG
88 terminology⁸ and classified into 3 categories (highly malignant, malignant, benign) per Westhall
89 et al.⁹ EEG assessment was made on the day of the MRI/MRS study.

90 **Neuroimaging**

91 ***MRI:***

92 MRI and MRS scans were performed on a 3T Siemens Verio MRI scanner using a 32-channel
93 head coil, on a mean of 6.4 ± 6.3 days (median 4.8 days) after cardiac arrest. Structural imaging
94 included 3D T1-weighted (MPRAGE: $1 \times 1 \times 1$ mm³, TR= 2530.0 ms, TE= 3.36 ms) and diffusion-
95 weighted images. Regional analysis of ADC images was carried out using FSL (Oxford Center
96 for Functional MRI of the Brain, Oxford, UK).¹⁰ ADC images were first co-registered to the T1
97 weighted image for each subject. The T1 images were then non-linearly registered to the
98 Montreal Neurologic Institute (MNI) Brain Atlas, and the same transformation was applied to the
99 ADC images. The success of automated registration was then manually confirmed. Artifacts
100 were removed by filtering out signal intensity less than 200 mm²/s, while CSF was removed by
101 filtering signal intensity greater than 2000 mm²/s. Regional anatomical masks were created
102 using a 50% probability map from the MNI atlas. Mean ADC signal intensity was then calculated
103 for each region. The percentage of whole brain and cortical voxels with ADC values < 650
104 mm²/s were similarly calculated from whole brain and cortical anatomical maps.

105 **MRS:**

106 Due to limitations imposed by the local institutional review board, MRS was obtained only with a
107 concurrent clinically indicated MRI. MRS was performed in four brain regions using a single
108 voxel PRESS sequence (TE=30ms, TR=2000ms, 20x20x20 mm³, 128 averages). The use of a
109 short echo time allows for the characterization of additional metabolites other than NAA, Cr, and
110 Cho, such as glutamate, glutamine, and myoinositol. Previous studies utilized long echo times
111 (TE > 144 ms) whereby these additional metabolites can no longer be detected due to their
112 relatively fast relaxation times. Brain regions include the PCG, PWM, left BG, and BS as shown
113 in Figure 1. The reason for selecting the PCG and PWM is that these regions have been shown
114 to be highly sensitive to anoxic/hypoxic injury¹¹ and are sites of reduced cerebral perfusion.¹²
115 The BG and BS were acquired so that they could be compared to other MRS studies in anoxia³⁻
116 ⁵. Anatomical landmarks from the T1-weighted images determined voxel locations, and
117 subsequently, automated optimization (3D shimming, transmit gain, frequency adjustment, and
118 water suppression) was performed on the voxel. When necessary, MRI technicians manually
119 shimmed to a line width of <15 Hz of the full-width half maximum (FWHM) of the unsuppressed
120 water spectrum in the basal ganglia and brainstem. Manual shimming was not required for the
121 PCG or PWM as both of these regions have excellent B0 homogeneity. This is another
122 advantage of utilizing these voxel locations. MRS of the BG (2 patients) and BS (12 patients)
123 were not obtained due to time constraints.

124 Single-voxel MRS raw data were pre-processed using singular value decomposition
125 (SVD)-based channel combination, spectral registration to correct for frequency drift, and water
126 suppression using the Hankel SVD method and OpenMRSLab.¹³ Metabolites were then fit and
127 quantified using linear combination models (LCModel)¹⁴ yielding the following measurements:
128 total NAA (including NAA + NAA-Glutamate), total creatine (Cr, including Cr + PhosphoCr), total
129 Cho (including PhosphoCho + Cho), Glutamate (Glu), Glutamine (Gln), Glutamate+Glutamine
130 (Glx), myoinositol (ml), and lactate (Lac). Cr concentrations were not significantly different

131 between the different cohorts and therefore used to normalize the data across the study.
132 Normative control scans used for comparison were acquired using the same scan protocol
133 (PCG and PWM) and on the same scanner.

134 In all subjects, major metabolites of NAA, Cr, Cho, and ml had Cramer-Rao Lower
135 Bounds (CRLB) of less than 20%. Due to the high CRLB of Lac at very low concentrations, the
136 data was not filtered to include subjects with low Lac to avoid any study bias.¹⁵

137 **Statistical Analysis:**

138 Comparative statistics (Student's independent samples t-test, Fisher's exact test, Wilcoxon
139 rank-sum test) were used as appropriate. Statistically significant results were evaluated using a
140 multivariable logistic regression model with dichotomized coma recovery as well as CPC at
141 hospital discharge (1-2 vs 3-5) as dependent variables. Correlations between variables of
142 interest were assessed using Spearman's correlation with 95% confidence intervals. Multiple
143 comparisons were adjusted for using a false discovery rate set at 0.05.¹⁶ P-values presented in
144 the manuscript text are the raw p-values; all p-values are also presented in Tables 1 and 2 with
145 an indication of their statistical significance after adjustment for multiple comparisons. Receiver
146 operating characteristic (ROC) analyses were performed to obtain discrimination thresholds.
147 Calculations were performed using R 3.3.2 (www.R-project.org).

148 **Classification of Evidence:**

149 The study provides Class IV evidence of MRS changes in anoxic brain injury after cardiac
150 arrest.

151 **Standard Protocol Approvals, Registration, and Patient Consents:**

152 The Institutional Review Board approved this study, and consent was obtained for each
153 patient by the legally authorized representative unless MRS was performed as part of clinical
154 care.

155 **Data Availability Policy**

156 Data will be shared at the request of other investigators for purposes of replicating procedures
157 and results.

158

159 **Results:**

160 **Characteristics of Study Cohort**

161 A total of 51 comatose patients after cardiac arrest underwent TTM, cEEG, MRI, and MRS. One
162 patient was excluded due to presentation with a large posterior circulation stroke immediately
163 before cardiac arrest, resulting in a total of 50 patients who underwent analysis. Of these, 14
164 had coma recovery, of whom 7 returned cognitively to baseline; all patients had benign EEGs
165 (Table 1). Three patients who did not have coma recovery survived, remaining comatose at
166 hospital discharge (CPC=4). One patient was awake, spontaneously moving extremities, and
167 was noted to follow 1-step commands approximately 75% of the time (CPC=3). There were no
168 meaningful differences in age, sex, or race. Patients who recovered were statistically
169 significantly more likely to have intact corneal reflexes (100% vs 55.6%, $p=0.002$) and motor
170 movements better than flexion (100% vs 11.1%, $p<0.001$).

171 MRS peaks were evaluated for effect of time elapsed to scan after cardiac arrest. Time
172 to scan revealed a statistically significant positive correlation with NAA/Cr ($r_s=0.43$ 95%
173 confidence interval = [0.17, 0.63], $p=0.002$) and a negative correlation with log(Lac/Cr) ($r_s=-0.40$
174 [-0.11, -0.60], $p=0.007$).

175

176 **Persistent coma is associated with reduced NAA/Cr and increased Lac/Cr** 177 **compared to patients with coma recovery and control subjects**

178 PCG NAA/Cr was statistically significantly lower in patients who did not have coma recovery as
179 compared to those who did (0.82 vs 1.26, $p<0.001$), with an AUC of 0.96 (Tables 1 and 2,
180 Figure 2). The Optimal cut-off, defined as the value-maximizing Youden's J statistic¹⁷, was 1.11
181 for a sensitivity of 85.7 and specificity of 86.5%. None of the patients with an NAA/Cr ratio under

182 0.98 recovered; 33% of patients between 0.98 and 1.2 recovered, and all patients above 1.2
183 recovered. PCG NAA/Cr was significantly lower in patients who died, as compared to those who
184 survived (mean NAA/Cr ratio of 0.79 vs 1.20, $p < 0.001$).

185 PCG Lac/Cr was statistically significantly higher in patients who did not have coma
186 recovery (0.39 vs 0.04, $p < 0.001$, Table 2), with an ROC AUC of 0.91. There was one outlier
187 survivor whose Lac/Cr was higher than expected (0.136). Although included for purposes of
188 completeness, there were technical difficulties with the scan; a water reference was not
189 obtained, which may have affected scaling ratios.

190 PCG Lac/Cr was also compared to peak serum lactate during admission, and serum
191 lactate level in closest proximity to the MRS scan, all but one of which were within 72 hours.
192 There was no statistically significant relationship between PCG MRS Lac/Cr peak and peak
193 serum lactate ($r_s = 0.09$, 95% CI [-0.20, 0.36]) or with serum lactate in the proximity of the MRS
194 ($r_s = 0.17$ [-0.12, 0.42]).

195 In the PWM, BG, and BS, there were smaller differences in NAA/Cr and Lac/Cr between
196 patients who did or did not achieve coma recovery. Only differences in Lac/Cr peaks reached
197 statistical significance before multiple comparisons correction in the WM and BG.

198

199 **Patients with coma recovery have reduced NAA/Cr as compared to control** 200 **subjects**

201 Patients were compared to control subjects with no history of brain injury or trauma. In patients
202 without coma recovery, the following statistically significant changes were observed:

- 203 - Decrease in NAA/Cr (PCG [0.82 vs 1.40, $p < 0.001$], PWM [1.48 vs 1.87, $p < 0.001$],
204 adjusted for multiple comparisons)
- 205 - Decrease in GABA (PCG [0.19 vs 0.27, $p < 0.001$], PWM [0.20 vs 0.23, $p < 0.001$]),
- 206 - Decrease in glutamate (PCG [0.97 vs 1.24, $p < 0.001$])
- 207 - Decrease in Glx (PCG [1.74 vs 2.10, $p = 0.010$], PWM [1.18 vs 1.36, $p < 0.001$])

- 208 - Decrease in MI/Cr (PCG [0.55 vs 0.75, $p<0.001$])
- 209 - Increase in Lac/Cr (PCG [0.39 vs 0.073, $p<0.001$] and PWM [0.43 vs 0.22, $p<0.001$])
- 210 - Increase in glutamine/Cr (PCG [1.12 vs 0.48, $p<0.001$], PWM [0.47 vs 0.30, $p<0.001$]).

211 In patients with coma recovery, NAA/Cr was significantly lower (PCG [1.26 vs 1.40,
212 $p<0.001$], PWM [1.71 vs 1.87, $p=0.008$], in addition to a decrease in glutamate (PCG [1.12 vs
213 1.24, $p=0.030$]), and an increase in glutamine (PWM [0.41 vs 0.30, $p=0.003$]). No other peaks
214 were statistically significantly different between the two populations, specifically, no difference in
215 Lac/Cr was seen. These changes were still present in patients with coma recovery who had a
216 cognitive return to baseline; NAA/Cr were lower in PCG (1.26 vs 1.40, $p=0.001$) and PWM (1.76
217 vs 1.87, $p=0.035$) and glutamine/Cr elevated (0.43 vs 0.30, $p=0.020$). These findings suggest
218 that patients with coma recovery still sustained an anoxic injury, but not at the same scale as
219 the non-recovered patients.

220

221 **Reduced MRI ADC signal intensity is associated with NAA/Cr reduction and** 222 **lactate elevation**

223 There were significant reductions in MRI ADC measures in patients who did not have coma
224 recovery in the whole brain, cortex, hippocampus, and white matter, with the cortex being most
225 significantly affected (Table 1). Correlation between PCG NAA/Cr and ADC values were
226 examined for mean total brain ADC as well as mean ADC values for individual brain regions.

227 There were significant correlations with the cerebellum, cortex, hippocampus, globus pallidus,
228 putamen, BG (combined), and white matter regions. Correlation between NAA/Cr and ADC was
229 linear (Figure 3), and it was strongest with cortical ADC values ($r_s=0.65$ [0.45, 0.79], $p<0.001$).

230 In comparison, there was a negative log-linear relationship between PCG Lac/Cr and cortical
231 ADC ($r_s=-0.74$ [-0.58, -0.84], $p<0.001$).

232 White matter ADC values were correlated to PWM Lac/Cr ($r_s=-0.46$ [-0.35, -0.74],
233 $p=0.0044$) with a trend towards correlation with PWM NAA/Cr ($r_s=0.28$ [-0.0001, 0.52], $p=0.052$).

234 Basal ganglia ADC values were correlated to NAA/Cr ($r_s=0.39$ [0.008, 0.68], $p=0.047$) with a
235 tend towards correlation with Lac/Cr ($r_s=-0.41$ [-0.023, 0.69] but $p=0.06$ after multiple
236 comparisons). Correlations between PWM and BG metabolites and ADC values from
237 corresponding brain regions were otherwise not statistically significant.

238

239 **Continuous background on EEG is associated with higher NAA/Cr; suppressed or burst**
240 **suppressed EEGs are associated with Lac/Cr production**

241 Patients who had a continuous EEG background had higher NAA/Cr than patients with a
242 discontinuous background (0.79 vs 1.18, $p<0.001$), and less likely to have a Lac/Cr over 0.14 (5
243 of 21 vs 26 of 29, $p<0.001$). Patients who did not recover from coma nearly always had
244 discontinuous, burst suppressed, or completely suppressed EEGs whereas all patients who
245 recovered had a continuous background on EEGs (Table 1). Reactivity to stimulation, though
246 not tested or determinable in all patients, was more often present in patients who recovered
247 ($p<0.001$). There were no differences in the number of patients who had status epilepticus,
248 generalized periodic discharges, or myoclonus. All patients with suppressed EEG backgrounds
249 at the time of MRS/MRI scans had elevated PCG Lac/Cr peaks of at least 0.331. All patients
250 with burst suppressed EEGs had PCG Lac/Cr peaks of at least 0.167.

251 In patients who did not achieve coma recovery, Lac/Cr was lower in patients who
252 experienced a seizure during any time of their hospitalization than patients who did not (0.452
253 vs 0.163, $p=0.0048$). No changes in lactate in relation to seizures were seen in patients who
254 achieved coma recovery.

255

256 **Discussion:**

257 This study demonstrates the spectrum of metabolic changes on MRS in patients after anoxic
258 brain injury; relationships with clinical, MRI, and electrographic markers of anoxic brain injury
259 were as follows:

- 260 1. Poor coma recovery was associated with a decrease in PCG NAA/Cr by approximately
261 35% and elevated lactate production (in our cohort, Lac/Cr >0.14).
- 262 2. MRS assessment had the highest association with coma recovery in the PCG as
263 compared to PWM, BG, or BS.
- 264 3. There is a linear relationship between cortical ADC values on MRI and PCG NAA/Cr and
265 there is an exponential increase in PCG lactate with decreasing cortical ADC, (e.g.
266 increasing cortical diffusion restriction).
- 267 4. Continuous background on EEG was associated with higher PCG NAA/Cr; EEGs that
268 are suppressed or burst suppressed at the time of the MRS were universally associated
269 with lactate production.

270

271 We observed a decrease in NAA/Cr values in patients with coma recovery as compared
272 to normative control subjects. This decrease persisted even in patients who had cognitive return
273 to baseline at bedside exam, though full neuropsychological evaluations were not performed.
274 We hypothesize that this is likely the result of mild anoxic injury, rather than TTM itself exerting
275 non-specific changes in the MRS spectra once the patient has been rewarmed. It is unclear
276 whether these patients experienced more subtle longer-term cognitive or other deficits, despite
277 their good functional outcome at hospital discharge. Previous studies have demonstrated long-
278 term cognitive deficits in >40% of survivors of cardiac arrest.¹⁸ Interventions in addition to TTM
279 to preserve structural and metabolic integrity after resuscitation to optimize neurological
280 recovery, even in patients who appear to have excellent in-hospital outcomes, should be
281 explored in future studies. Recent preclinical and clinical studies have suggested promising
282 effects of noble gases¹⁹ and citicoline²⁰ as neuroprotective agents.

283 Our cohort demonstrates a tight coupling between NAA/Cr and MRI ADC values. ADC
284 measures the impedance of water molecule diffusion and assesses cell membrane integrity.²¹
285 NAA is a molecule found in the brain at high concentrations that is sensitive in a nonspecific

286 manner to several neurologic disorders and has been postulated to be a marker of neuronal
287 health and bioenergetic dysfunction.^{22, 23} The high degree of linear correlation of these two
288 disparate measurements in the cortex further suggests that the cortex has the greatest
289 sensitivity to anoxic injury, as compared to other sampled brain regions.

290 This study also highlights the importance of the appearance of a lactate peak. Although
291 there was an overlap of NAA/Cr and ADC values in patients who had coma recovery vs those
292 who did not, the appearance of a lactate peak in the PCG with a concentration of 0.14, on the
293 other hand, was more consistently associated with the absence of coma recovery.

294 Electrographically, complete background suppression or burst suppression, which are patterns
295 that have been demonstrated to be associated with poor outcome in multiple studies^{9, 24}, were
296 consistently associated with a lactate peak. As such, the emergence of a lactate peak may
297 represent a point of irreversible brain injury from which coma recovery is not possible.

298 As such, we hypothesize that MRS changes provide an in-vivo view of the major
299 pathophysiological processes in anoxic brain injury that may occur at different severities (Figure
300 5). NAA/Cr may be representative of early injury that may be most sensitive but potentially
301 nonspecific for poor outcome. Most patients with a mild decrease in NAA/Cr and ADC achieve
302 coma recovery. Increasing severity of injury results in only a portion of patients recovering.
303 Injury severe enough to cause an increase in lactate represents severe, potentially irreversible
304 anoxic injury. Lactate levels as measured by MRS have been demonstrated to be a reliable
305 marker of outcome after stroke.²⁵ In a rat model, hypothermia induced neuroprotection-related
306 metabolic changes were seen, including an increase in Lac and MI, and a decrease in Glu.²⁶

307 The mechanism of elevated lactate peak in severe anoxic injury may be viewed in terms
308 of the integrity of oxidative metabolism. Rapid depletion of ATP after cessation of cerebral
309 perfusion causes failure in the membrane ATP-dependent Na/K pumps, resulting in a massive
310 influx of Na, efflux of K, and membrane depolarization. This results in opening voltage-gated Ca
311 channels resulting in large increases in intracellular Ca, activation of Ca-dependent K channels,

312 resulting in further loss of selective membrane permeability.²⁷ Lactate levels rise almost
313 immediately occurs as a result of a switch to anaerobic glycolysis, which quickly returns to
314 baseline if perfusion is restored and normal mitochondrial function is resumed. Accumulation of
315 lactate after re-establishment of perfusion is due to secondary energy failure in which neurons
316 that survive the initial insult develop energy depletion from mitochondrial failure^{28, 29}; elevated
317 MRS lactate at 48 hours is associated with cell death and microglial activation in animal
318 models³⁰, and the accumulation of lactate portended an extremely poor outcome in pediatric
319 hypoxic-ischemic injury.^{31, 32} Failure to re-establish membrane gradient results in cytotoxic
320 edema, cessation of cerebral perfusion, and neuronal transmission.

321 The failure of oxidative metabolism, as evidenced by lactate generation and its
322 relationship to synaptic activity, may account for the consistent findings of either burst
323 suppression or severe background voltage suppression seen in this cohort. Approximately 75-
324 80% of the brain's energy requirements are for signal processing, predominantly for the
325 generation of action potentials and postsynaptic actions of neurotransmitters, predominantly
326 glutamate.^{33, 34} The generation of EEG signals is due to a summation of local field potentials, the
327 most important source of which is synaptic activity³⁵. Varying levels of damage to the excitatory
328 synapses have been demonstrated to recapitulate the various EEG abnormalities seen in
329 postanoxic EEGs, including burst suppression and discontinuous low voltage recordings.³⁶
330 Although it is likely that presynaptic ischemic failure is the initial cascade in inhibiting synaptic
331 transmission in mild-moderate ischemia,³⁴ severe and widespread failure in synaptic
332 transmission is likely coupled to the impairment of oxidative metabolism.

333 One unexpected finding is the increase in glutamine in patients with poor outcomes.
334 Glutamate and glutamine are preferentially used as metabolic and cataplerotic substrates in the
335 Krebs cycle during anoxia and ischemia. They may also function as reservoirs to protect against
336 post-ischemic reduction in cardiac output by maintaining metabolic intermediates. The
337 biosynthesis of glutamine from glutamate amidation is catalyzed by the enzyme glutamine

338 synthetase (GS); after the release and reuptake of glutamate into neurons and glia, glutamate is
339 catalyzed back to glutamine and ammonium by mitochondrial phosphate-activated glutaminase
340 (PAG). GS activity increases in response to acute hypoxic-ischemic nervous system injury in
341 children and other compensatory mechanisms prevail in the case of chronic hypoxic-ischemic
342 insults.³⁷ In cell culture models of hypoxia, PAG activity is inhibited, potentially by the acidic pH
343 induced by lactic acidosis.^{38, 39} The combination of increased glutamine synthetase activity and
344 inhibition of phosphate-activated glutaminase may play a rescue role in preventing glutamate-
345 induced injury. Separating the glutamine and glutamate resonances remains challenging, and
346 further studies are required to confirm these findings.

347 Our study is in agreement with a large European study that demonstrated that NAA/Cr
348 ratios measured in the pons and thalami were significantly lower in patients with unfavorable as
349 compared to favorable outcomes for MRI/MRS obtained between 7 and 28 days after cardiac
350 arrest.³ Differences from our study include that their study reported only MRS values of the
351 thalamus and pons, included patients both patients who did and did not undergo TTM, and
352 included only patients who had survived for 7 days after cardiac arrest. PCG is more sensitive
353 for identifying MRS changes when compared to the PWM, BG, and BS. Furthermore, we
354 demonstrate a robust correlation between single voxel spectra of the PCG and both cortical and
355 whole-brain ADC, suggesting that spatial sampling bias may be less relevant as loss of
356 perfusion as well as reperfusion is global. Future studies with multivoxel spectroscopy will help
357 to fully elucidate regional variations.

358 **Study Limitations**

359 The sample size is too small to develop a multimodal outcome prediction model. This
360 also likely explains the lack of association between coma recovery and status epilepticus,
361 generalized periodic discharges, or myoclonus. The cut-off values are thus representative of
362 only our dataset. Voxel selection did not target regions of greatest ADC or T2 changes on MRI
363 scans, potentially decreasing MRS effect size. However, this minimized variability in

364 signal/noise characteristics of different brain regions and allowed the generalizability of findings
365 across subjects. As MRS scans were only obtained with a clinically necessary MRI scan, there
366 is variability in the timing of the image acquisition and potential selection bias. Although there
367 were correlations between time elapsed to scan and MRS peaks, this may reflect a strong bias
368 for patients with clinical suspicion of poor outcome to be scanned earlier in their course of
369 hospitalization. Previous MRS studies in stroke²⁵ and neonatal hypoxic-ischemic injury⁴⁰
370 demonstrated a sustained decrease in NAA and a more transient increase in Lac. Without
371 longitudinal MRS data, we are unable to determine the nature of MRS peak changes over time.
372 Cortical ADC values of survivors are higher than typically seen in other studies, likely due to our
373 selection of a more conservative cut-off value of 2000 mm²/s to remove artifacts⁴¹, likely
374 resulting in the inclusion of high ADC CSF voxels. Nonetheless, our results remained robust
375 across a range of other cut-off values (1000 mm²/s and 1500 mm²/s).

376 NSE and SSEPs were not routinely obtained on every patient, and a pupillometer was
377 not utilized. We assessed cognitive return to baseline to the patient's estimated premorbid
378 baseline on bedside exam. A detailed neuropsychological evaluation, which was not performed,
379 would be required to fully assess residual deficits. WLST was performed on a case-by-case
380 basis and may potentially conflict with objective prognostic measures and treating clinicians
381 were aware of the MRS results. The choice of coma recovery defined as following commands,
382 rather than CPC, as the primary clinical outcome, minimized the effect of these variabilities.

383 As with any testing modality, care must be taken in avoiding overreliance on a single
384 measure including the MRS, as demonstrated by one patient who underwent 2 MRS scans. A
385 female in her 40's sustained a PEA arrest, thereafter experienced myoclonic status epilepticus.
386 MRI/MRS were obtained 4 days and 7 days after cardiac arrest; while neither scan revealed
387 lactate or ADC changes, NAA/Cr of the basal ganglia decreased 20.9% between the two scans.
388 The patient eventually made a full recovery, without chronic seizures or observable cognitive
389 deficits on long-term follow-up.

390

391 **Conclusions:**

392 This study shows marked differences in several MRS detectable metabolites in cardiac arrest
393 patients undergoing TTM who achieved coma recovery, as compared to those who did not.
394 NAA/Cr and diffusion restriction changes are linearly correlated. The increasing severity of the
395 injury is associated with the emergence of a rapidly increasing lactate peak, which was
396 associated with either burst or complete suppression on EEG, and from which no patients
397 recovered. Metabolic changes may be seen after TTM as compared to normative controls even
398 in patients with presumed excellent recovery. This suggests that some amount of neuronal
399 injury and breakdown in cellular microarchitecture may be tolerated, whereas compromise to
400 aerobic oxidative metabolism represents severe, potentially irreversible anoxic brain injury.

401

402 **References**

- 403 1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics—2016 Update.
404 *Circulation* 2016;133:e38-e360.
- 405 2. Greer DM, Rosenthal ES, Wu O. Neuroprognostication of hypoxic-ischaemic coma in the
406 therapeutic hypothermia era. *Nature reviews Neurology* 2014;10:190-203.
- 407 3. Velly L, Perlberg V, Boulier T, et al. Use of brain diffusion tensor imaging for the prediction of long-
408 term neurological outcomes in patients after cardiac arrest: a multicentre, international, prospective,
409 observational, cohort study. *Lancet Neurol* 2018;17:317-326.
- 410 4. Alderliesten T, De Vries LS, Staats L, et al. MRI and spectroscopy in (near) term neonates with
411 perinatal asphyxia and therapeutic hypothermia. *Archives of Disease in Childhood: Fetal and Neonatal*
412 *Edition* 2017;102:F147-F152.
- 413 5. Sijens PE, Wischniowsky K, ter Horst HJ. The prognostic value of proton magnetic resonance
414 spectroscopy in term newborns treated with therapeutic hypothermia following asphyxia. *Magnetic*
415 *Resonance Imaging* 2017;42:82-87.
- 416 6. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet* 1975;1:480-484.
- 417 7. Szumita PM, Baroletti S, Avery KKR, et al. Implementation of a Hospital-wide Protocol for Induced
418 Hypothermia Following Successfully Resuscitated Cardiac Arrest. *Critical pathways in cardiology*
419 2010;9:216-220.
- 420 8. Hirsch LJ, LaRoche SM, Gaspard N, et al. American Clinical Neurophysiology Society's Standardized
421 Critical Care EEG Terminology: 2012 version. *J Clin Neurophysiol* 2013;30:1-27.
- 422 9. Westhall E, Rossetti AO, van Rootselaar AF, et al. Standardized EEG interpretation accurately
423 predicts prognosis after cardiac arrest. *Neurology* 2016;86:1482-1490.
- 424 10. Jehi L, Yardi R, Chagin K, et al. Development and validation of nomograms to provide
425 individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis. *The Lancet*
426 *Neurology* 2015;14:283-290.
- 427 11. Kreis R, Arcinue E, Ernst T, Shonk TK, Flores R, Ross BD. Hypoxic encephalopathy after near-
428 drowning studied by quantitative 1H-magnetic resonance spectroscopy. Metabolic changes and their
429 prognostic value. *Journal of Clinical Investigation* 1996;97:1142-1154.
- 430 12. Lawley JS, Macdonald JH, Oliver SJ, Mullins PG. Unexpected reductions in regional cerebral
431 perfusion during prolonged hypoxia. *The Journal of Physiology* 2016;00:1-13.
- 432 13. Rowland BC, Liao H, Adan F, Mariano L, Irvine J, Lin AP. Correcting for Frequency Drift in Clinical
433 Brain MR Spectroscopy. *Journal of Neuroimaging* 2017;27:23-28.
- 434 14. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR
435 spectra. *Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in*
436 *Medicine / Society of Magnetic Resonance in Medicine* 1993;30:672-679.
- 437 15. Kreis R. The trouble with quality filtering based on relative Cramer-Rao lower bounds. *Magn Reson*
438 *Med* 2016;75:15-18.
- 439 16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach
440 to multiple testing. *Journal of the Royal Statistical Society B* 1995;57:289-300.
- 441 17. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;3:32-35.
- 442 18. Steinbusch CVM, van Heugten CM, Rasquin SMC, Verbunt JA, Moolaert VRM. Cognitive
443 impairments and subjective cognitive complaints after survival of cardiac arrest: A prospective
444 longitudinal cohort study. *Resuscitation* 2017;120:132-137.
- 445 19. Nespoli F, Redaelli S, Ruggeri L, Fumagalli F, Olivari D, Ristagno G. A complete review of preclinical
446 and clinical uses of the noble gas argon: Evidence of safety and protection. *Ann Card Anaesth* 2019;22:122-
447 135.
- 448 20. Salamah A, Mehrez M, Faheem A, El Amrousy D. Efficacy of Citicoline as a Neuroprotector in
449 children with post cardiac arrest: a randomized controlled clinical trial. *Eur J Pediatr* 2020.

- 450 21. Sener RN. Diffusion MRI: apparent diffusion coefficient (ADC) values in the normal brain and a
451 classification of brain disorders based on ADC values. *Comput Med Imaging Graph* 2001;25:299-326.
- 452 22. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from
453 neurodiagnostics to neurobiology. *Prog Neurobiol* 2007;81:89-131.
- 454 23. Pan JW, Takahashi K. Interdependence of N-acetyl aspartate and high-energy phosphates in
455 healthy human brain. *Ann Neurol* 2005;57:92-97.
- 456 24. Ruijter BJ, Tjepkema-Cloostermans MC, Tromp SC, et al. Early electroencephalography for
457 outcome prediction of postanoxic coma: A prospective cohort study. *Ann Neurol* 2019;86:203-214.
- 458 25. Munoz Maniega S, Cvorov V, Chappell FM, et al. Changes in NAA and lactate following ischemic
459 stroke: a serial MR spectroscopic imaging study. *Neurology* 2008;71:1993-1999.
- 460 26. Chan K W Y, Chow AM, Chan KC, Yang J, Wu EX. Magnetic resonance spectroscopy of the brain
461 under mild hypothermia indicates changes in neuroprotection-related metabolites. *Neuroscience Letters*
462 2010;475:150-155.
- 463 27. Schramm AE, Carton-Leclercq A, Diallo S, et al. Identifying neuronal correlates of dying and
464 resuscitation in a model of reversible brain anoxia. *Prog Neurobiol* 2020;185:101733.
- 465 28. Lorek A, Takei Y, Cady EB, et al. Delayed ("secondary") cerebral energy failure after acute hypoxia-
466 ischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance
467 spectroscopy. *Pediatr Res* 1994;36:699-706.
- 468 29. Huang BY, Castillo M. Hypoxic-ischemic brain injury: imaging findings from birth to adulthood.
469 *Radiographics* 2008;28:417-439; quiz 617.
- 470 30. Pang R, Martinello KA, Meehan C, et al. Proton Magnetic Resonance Spectroscopy Lactate/N-
471 Acetylaspartate Within 48 h Predicts Cell Death Following Varied Neuroprotective Interventions in a Piglet
472 Model of Hypoxia-Ischemia With and Without Inflammation-Sensitization. *Front Neurol* 2020;11:883.
- 473 31. Penrice J, Cady EB, Lorek A, et al. Proton magnetic resonance spectroscopy of the brain in normal
474 preterm and term infants, and early changes after perinatal hypoxia-ischemia. *Pediatr Res* 1996;40:6-14.
- 475 32. Lally PJ, Montaldo P, Oliveira V, et al. Magnetic resonance spectroscopy assessment of brain injury
476 after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study. *The*
477 *Lancet Neurology* 2019;18:35-45.
- 478 33. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. *J Cereb*
479 *Blood Flow Metab* 2001;21:1133-1145.
- 480 34. Hofmeijer J, van Putten MJ. Ischemic cerebral damage: an appraisal of synaptic failure. *Stroke*
481 2012;43:607-615.
- 482 35. Buzsaki G, Anastassiou CA, Koch C. The origin of extracellular fields and currents--EEG, ECoG, LFP
483 and spikes. *Nat Rev Neurosci* 2012;13:407-420.
- 484 36. Ruijter BJ, Hofmeijer J, Meijer HGE, van Putten M. Synaptic damage underlies EEG abnormalities
485 in postanoxic encephalopathy: A computational study. *Clin Neurophysiol* 2017;128:1682-1695.
- 486 37. Dao DN, Ahdab-Barmada M, Schor NF. Cerebellar glutamine synthetase in children after hypoxia
487 or ischemia. *Stroke* 1991;22:1312-1316.
- 488 38. Kobayashi S, Millhorn DE. Hypoxia regulates glutamate metabolism and membrane transport in
489 rat PC12 cells. *J Neurochem* 2001;76:1935-1948.
- 490 39. Chandrasekaran VP, Viswanathan R, Venkatasubramanian TA. Glutamine synthetase, glutaminase
491 and phosphodiesterase activities in brain under hypoxia: in vitro effect of cortisol, GABA and serotonin on
492 glutamine synthetase. *Environ Physiol Biochem* 1975;5:373-377.
- 493 40. Shibasaki J, Aida N, Morisaki N, Tomiyasu M, Nishi Y, Toyoshima K. Changes in Brain Metabolite
494 Concentrations after Neonatal Hypoxic-ischemic Encephalopathy. *Radiology* 2018;288:840-848.
- 495 41. Wu O, Sorensen AG, Benner T, Singhal AB, Furie KL, Greer DM. Comatose patients with cardiac
496 arrest: predicting clinical outcome with diffusion-weighted MR imaging. *Radiology* 2009;252:173-181.

498 **Figure Legends**

499

500 Figure 1: MRS voxel placement and representative spectra in patients with good and poor
501 outcome

502 Placement of the MRS voxels: A) Posterior cingulate gyrus (PCG); B) Posterior white matter
503 (PWM); C) Basal ganglia (BG); D) Brainstem (BS). Spectra of illustrative patients with good
504 outcomes (A1-D1) or poor outcomes (A2-D2).

505

506 Figure 2: Posterior cingulate gyrus (PCG) NAA/Cr ratios in patient populations
507 Boxplots of PCG NAA/Cr levels patients who had no coma recovery (did not follow commands),
508 recovery (followed commands), and normative control subjects

509

510 Figure 3: Relationship between cortical ADC vs posterior cingulate gyrus (PCG) NAA/Cr, PCG
511 lactate, and coma recovery

512 A) Linear relationship between cortical ADC and PCG NAA/Cr. The red line represents the
513 optimal cut-off for recovery to follow commands. B) Inverse log-linear relationship between
514 cortical ADC and PCG lactate. The red line represents the optimal cut-off for recovery to follow
515 commands. The blue line represents cut-off with the specificity of recovery set to 100%. C) and
516 D) Relationship between % of cortical voxels with ADC < 650 mm²/s and NAA/Cr (C) and log of
517 PCG lactate (D).

518

519 Figure 4: Illustration of the relationship between MRS, MRI, EEG, and outcome after cardiac
520 arrest

521 Summary of MRS and ADC peaks after TTM. NAA/Cr/Cr values higher than 0.98 and ADC
522 values over 1071 resulted in universal good come with coma recovery. The appearance of
523 lactate resulted in a poor outcome. Patients between these values (in purple) have the potential

524 for coma recovery. For illustrative purposes, diffusion-weighted images are shown rather than
525 ADC maps.

526 **Table 1: Characteristics of the study population**

	No coma recovery (n=36)	Coma recovery (n=14)	p-value
Age in years (standard deviation)	61.2 (11.9)	60.1 (15.0)	0.81
Sex			0.52
M	21 (58.3%)	10 (71.4%)	
†Pulseless rhythm			0.31
VT/VF	9 (25.7%)	6 (42.9%)	
Non-shockable	26 (74.3%)	8 (57.1%)	
CPC at discharge			<0.001*
1-2	0	12 CPC1=4 CPC2=8	
3-5	36 CPC4=3 CPC5=33	2 CPC3=1 CPC5=1	
‡CPC at 3-6 months			<0.001*
1-2	0	10 CPC1=6 CPC2=4	
3-5	36 CPC4=1 CPC5=35	3 CPC5=3	
Days to WLST (interquartile range)	6 (6)		

§Target temperature			0.52
33	31 (88.9%)	11 (84.7%)	
36	4 (11.1%)	2 (15.4%)	
Clinical exam			
Pupillary reflexes (%)	26 (72.2%)	14 (100%)	0.045
Corneal reflexes (%)	20 (55.6%)	14 (100%)	0.002*
Motor exam flexion or better (%)	4 (11.1%)	14 (100%)	<0.001*
MRI			
Median % whole brain voxels with ADC below 650 mm ² /s (range)	22.9 (1.2-95.9)	2.5 (0.9-6.1)	<0.001*
Median % cortical voxels with ADC under 650 mm ² /s (range)	19.6 (1.2-95.6)	2.1 (0.6-4.6)	<0.001*
Whole brain ADC (mean, sd)	869.7 (157.7)	998.7 (60.5)	<0.001*
Cortex ADC (mean, sd)	923.3 (108.7)	1080.4 (78.1)	<0.001*
White matter ADC (mean, sd)	777.1 (142.8)	828.3 (49.8)	<0.001*
Acc ADC (mean, sd)	835.6 (156.7)	880.7 (102.1)	0.24
Caudate ADC (mean, sd)	901.0 (170.4)	969.2 (116.0)	0.12
Putamen ADC (mean, sd)	717.6 (123.9)	796.4 (46.6)	0.002*
Thalamus ADC (mean, sd)	880.0 (128.8)	925.0 (46.7)	0.076
Basal ganglia ADC (mean, sd)	842.7 (130.7)	905.0 (73.2)	0.039
Amygdala ADC (mean, sd)	980.6 (158.8)	1002.1 (77.9)	0.53

Hippocampus ADC (mean, sd)	995.7 (175.2)	1089.0 (116.3)	0.035
Cerebellum ADC (mean, sd)	838.9 (150.5)	929.4 (82.7)	0.010*
EEG on day of MRI/MRS			
Continuous/nearly continuous	7 (19.4%)	14 (100%)	<0.001*
Discontinuous, burst suppressed, or completely suppressed	29 (80.6%)	0 (0%)	
Generalized periodic discharges	16 (44.4%)	9 (64.3%)	0.35
Myoclonus	6 (16.7%)	4 (28.6%)	0.44
Status epilepticus	6 (16.7%)	2 (14.3%)	1
Reactivity-yes	8 (33.3%)	10 (100%)	<0.001*
Reactivity-no	16 (66.7%)	0 (0%)	
Somatosensory evoked potential			
N20 present at least one limb	2	1	
Absent	1	0	
Neuron specific enolase			
>33ng/mL	6	1	
<33ng/mL	2	2	

527 *Statistically significant after correction for multiple comparisons (FDR=0.05). †Rhythm
528 unknown in one patient; ‡One patient lost to follow-up. §Fever avoided in 2 patients but did not
529 undergo TTM; ||Reactivity not tested or ascertainable in 16 patients. P-values not calculated for
530 somatosensory evoked potential studies and neuron specific enolase due to the small number
531 of subjects

532 **Table 2: MRS peaks vs outcome**

	No coma recovery (n=30) Median (IQR)	Coma recovery (n=12) Median (IQR)	p-value (Wilcoxon)
PCG			
NAA+NAAG/Cr	0.82 (0.29)	1.26 (0.17)	<0.001*
Lac/Cr	0.39 (0.51)	0.04 (0.06)	<0.001*
Glu/Cr	0.90 (0.25)	1.12 (0.24)	0.007*
Gln/Cr	1.01 (0.75)	0.49 (0.23)	<0.001*
Glx/Cr	2.10 (0.63)	1.56 (0.40)	0.002
MI/Cr	0.55 (0.23)	0.69 (0.15)	0.028
PWM			
NAA+NAAG/Cr	1.48 (0.33)	1.71 (0.19)	0.016
Lac/Cr	0.22 (0.23)	0.08 (0.11)	0.005
Glu/Cr	0.83 (0.17)	0.83 (0.23)	0.91
Gln/Cr	0.47 (0.37)	0.41 (0.16)	0.19
Glx/Cr	1.36 (0.41)	1.30 (0.45)	0.24
MI/Cr	0.80 (0.25)	0.77 (0.11)	0.89
BG			
NAA+NAAG/Cr	0.75 (0.19)	0.73 (0.15)	0.92
Lac/Cr	0.14 (0.18)	0.015 (0.080)	0.01
Glu/Cr	0.90 (0.19)	0.95 (0.16)	0.94
Gln/Cr	0.85 (0.57)	0.65 (0.22)	0.06
Glx/Cr	1.78 (0.61)	1.53 (0.41)	0.040

MI/Cr	0.53 (0.24)	0.62 (0.34)	0.37
BS			
NAA+NAAG/Cr	1.49 (0.33)	1.71 (0.19)	0.019
Lac/Cr	0.22 (0.23)	0.078 (0.11)	0.007
Glu/Cr	0.83 (0.17)	0.83 (0.23)	0.98
Gln/Cr	0.48 (0.36)	0.41 (0.16)	0.17
Glx/Cr	1.40 (0.42)	1.30 (0.45)	0.20
MI/Cr	0.79 (0.25)	0.77 (0.11)	0.97

533 *Statistically significant after correction for multiple comparisons (FDR=0.05); Glu: glutamine;

534 Glu: glutamate; Glx: Glu+Gln

535 **Table 3: ROC and cut-off values**

	AUC	Optimal cut-off	Sensitivity and specificity at optimal cut-off	Cut-off required for 100% sensitivity for coma recovery; specificity
PCG				
NAA/Cr	0.96	1.11	85.7%, 88.9%	0.98, 77.8%
Lac/Cr	0.91	0.14	83.3%, 92.9%	0, 0%
Lac/NAA	0.93	0.12	86.1%, 100.0%	0, 0%
PWM				
NAA/Cr	0.72	1.52	85.7%, 61.1%	1.23, 19.4%
Lac/Cr	0.76	0.16	66.7, 85.7%	0, 0%
Lac/NAA	0.77	0.091	65.7%, 85.7%	0, 0%
BG				
NAA/Cr	0.48	0.73	55.6%, 47.1%	0.64, 23.5%
Lac/Cr	0.81	0.112	70.6%, 88.9%	0, 0%
Lac/NAA	0.78	0.11	76.5%, 77.8%	0, 0%
BS				
NAA/Cr	0.56	1.92	50.0%, 76.0%	0.99, 8.0%
Lac/Cr	0.52	0.096	48.0%, 70.0%	0, 0%
Lac/NAA	0.48	0.058	45.8%, 60.0%	0, 0%
ADC				
Whole brain	0.75	908.0	100%, 58.3%	908.0, 58.3
Cortex	0.78	989.0	92.9%, 61.1%	950.0, 55.6%
Hippocampus	0.65	1051.4	64.3, 55.6%	921.6, 27.8%
Thalamus	0.57	927.6	50.0, 61.1%	856.7, 27.8%
White matter	0.76	821.9	92.9%, 61.1%	802.5, 58.3%
Basal ganglia	0.67	843.2	85.7%, 50.0%	806.2, 33.3%
Cerebellum	0.70	904.4	71.4%, 66.7%	810.7, 38.9%

537 Appendix 1: Authors

Jong Woo Lee, MD, PhD	Brigham and Women's Hospital	Design and conceptualized study; analyzed and interpreted the data; drafted the manuscript for intellectual content
Lasya Sreepada, BS	Brigham and Women's Hospital	Analyzed the data; drafted the manuscript for intellectual content
Matthew Bevers	Brigham and Women's Hospital	Interpreted the data; revised the manuscript for intellectual content
Karen Li, BBA	Brigham and Women's Hospital	Analyzed the data; revised the manuscript for intellectual content
Benjamin Scirica, MD	Brigham and Women's Hospital	Major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content
Danuzia Silva, RN	Brigham and Women's Hospital	Major role in the acquisition of data; revised the manuscript for intellectual content
Galen Henderson, MD	Brigham and Women's Hospital	Interpreted the data; revised the manuscript for intellectual content
Camden Bay, PhD	Brigham and Women's Hospital	Analyzed and interpreted the data; revised the manuscript for intellectual content
Alexander Lin, PhD	Brigham and Women's Hospital	Design and conceptualized study; analyzed and interpreted the data; drafted the manuscript for intellectual content

538

539

Figure 1




Figure 2




Figure 3




Figure 4

